<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ROBoto2: An Interactive System and Dataset for LLM-assisted Clinical Trial Risk of Bias Assessment - Health AI Hub</title>
    <meta name="description" content="This paper introduces ROBOTO2, an open-source, web-based platform designed to streamline the labor-intensive Risk of Bias (ROB v2) assessment of clinical trials">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>ROBoto2: An Interactive System and Dataset for LLM-assisted Clinical Trial Risk of Bias Assessment</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.03048v1" target="_blank">2511.03048v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-04
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Anthony Hevia, Sanjana Chintalapati, Veronica Ka Wai Lai, Thanh Tam Nguyen, Wai-Tat Wong, Terry Klassen, Lucy Lu Wang
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CL
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.03048v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.03048v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces ROBOTO2, an open-source, web-based platform designed to streamline the labor-intensive Risk of Bias (ROB v2) assessment of clinical trials using LLM-assisted methods. It also presents a new dataset of 521 pediatric clinical trial reports, annotated via both manual and LLM-assisted approaches, which serves as a benchmark for evaluating LLM performance in this critical systematic review task.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate risk of bias assessment is fundamental for evidence-based medicine, influencing the reliability of systematic reviews and meta-analyses, which in turn guides clinical practice and policy. Automating this process can significantly improve the efficiency, consistency, and timeliness of evaluating clinical trial quality, ultimately leading to more robust medical evidence for patient care.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application involves using Large Language Models (LLMs) to automate and assist in the critical process of assessing the risk of bias in clinical trials. This streamlines the evaluation of medical research quality, aiding researchers and clinicians in synthesizing evidence for informed healthcare decisions and developing medical guidelines.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>ROBOTO2 is an open-source, web-based platform facilitating LLM-assisted ROB v2 assessment of clinical trials.</li>
                    
                    <li>The system employs an interactive interface combining PDF parsing, retrieval-augmented LLM prompting, and human-in-the-loop review to provide preliminary answers and supporting evidence for signaling questions.</li>
                    
                    <li>Users can upload clinical trial reports, receive LLM-generated suggestions, and provide real-time feedback and corrections.</li>
                    
                    <li>A novel dataset of 521 pediatric clinical trial reports (8954 signaling questions, 1202 evidence passages) was constructed, annotated using both manual and LLM-assisted methods, and released publicly.</li>
                    
                    <li>The dataset serves as a public benchmark to foster reproducibility and enable future research in automating ROB assessment.</li>
                    
                    <li>The authors benchmarked the ROB2 performance of 4 different LLMs using their new dataset, analyzing current model capabilities and highlighting ongoing challenges.</li>
                    
                    <li>The platform, code, and data are publicly available to encourage adoption and further research in this domain.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The methodology involved developing ROBOTO2, an interactive web-based platform incorporating PDF parsing and retrieval-augmented LLM prompting with a human-in-the-loop feedback mechanism. A dataset of 521 pediatric clinical trial reports was manually and LLM-assisted annotated to create 8954 signaling questions with 1202 evidence passages. This dataset was then used to benchmark the ROB2 performance of 4 different LLMs.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The paper demonstrates the feasibility and utility of an LLM-assisted platform for streamlining ROB2 assessment. The benchmarking results for 4 LLMs, while not explicitly detailed in performance metrics within the abstract, provided an analysis into current model capabilities and highlighted ongoing challenges in fully automating this complex aspect of systematic review.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>ROBOTO2 has the potential to significantly reduce the time and effort required for risk of bias assessment in clinical trials, accelerating the production of systematic reviews and meta-analyses. This efficiency gain allows researchers and clinicians to access synthesized, high-quality evidence more rapidly, informing clinical guidelines, treatment decisions, and healthcare policy with greater speed and consistency. The platform's interactive nature also supports quality control and training for reviewers.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract points to "ongoing challenges in automating" ROB assessment, implying that while LLMs provide significant assistance, full automation without human oversight remains a complex task with current model limitations. The specific performance metrics or areas of weakness for the benchmarked LLMs are not detailed in the abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The release of the ROBOTO2 platform, code, and the new pediatric clinical trial dataset is explicitly stated to foster reproducibility and enable future research. This includes further development of LLM capabilities for ROB assessment, exploration of different LLM architectures, and expansion of the dataset to cover diverse medical domains and trial types.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Systematic Reviews</span>
                    
                    <span class="tag">Evidence-Based Medicine</span>
                    
                    <span class="tag">Clinical Research</span>
                    
                    <span class="tag">Pediatrics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Risk of Bias</span>
                    
                    <span class="tag tag-keyword">Clinical Trials</span>
                    
                    <span class="tag tag-keyword">Large Language Models</span>
                    
                    <span class="tag tag-keyword">Systematic Review</span>
                    
                    <span class="tag tag-keyword">Retrieval-Augmented Generation</span>
                    
                    <span class="tag tag-keyword">Pediatrics</span>
                    
                    <span class="tag tag-keyword">Human-in-the-loop</span>
                    
                    <span class="tag tag-keyword">Evidence-Based Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">We present ROBOTO2, an open-source, web-based platform for large language
model (LLM)-assisted risk of bias (ROB) assessment of clinical trials. ROBOTO2
streamlines the traditionally labor-intensive ROB v2 (ROB2) annotation process
via an interactive interface that combines PDF parsing, retrieval-augmented LLM
prompting, and human-in-the-loop review. Users can upload clinical trial
reports, receive preliminary answers and supporting evidence for ROB2 signaling
questions, and provide real-time feedback or corrections to system suggestions.
ROBOTO2 is publicly available at https://roboto2.vercel.app/, with code and
data released to foster reproducibility and adoption. We construct and release
a dataset of 521 pediatric clinical trial reports (8954 signaling questions
with 1202 evidence passages), annotated using both manually and LLM-assisted
methods, serving as a benchmark and enabling future research. Using this
dataset, we benchmark ROB2 performance for 4 LLMs and provide an analysis into
current model capabilities and ongoing challenges in automating this critical
aspect of systematic review.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>EMNLP 2025 System Demonstration</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>